Obstacles Impeding The Development of Nanocarriers for Anticancer Drugs

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. doi: 10.3322/caac.21660 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Miller KD , NogueiraL, MariottoABet al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin.69(5), 363–385 (2019).
   PubMed Web of Science ®Google Scholar
• Youn YS , BaeYH. Perspectives on the past, present, and future of cancer nanomedicine. Adv. Drug Deliv. Rev.130, 3–11 (2018).
   PubMed Web of Science ®Google Scholar
• Sun T , ZhangYS, PangB, HyunDC, YangM, XiaY. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl.53(46), 12320–12364 (2014).
   PubMed Web of Science ®Google Scholar
• Xing R , LiuK, JiaoTet al. An injectable self-assembling collagen-gold hybrid hydrogel for combinatorial antitumor photothermal/photodynamic therapy. Adv. Mater.28(19), 3669–3676 (2016).
   PubMed Web of Science ®Google Scholar
• Liu Y , BhattaraiP, DaiZ, ChenX. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem. Soc. Rev.48(7), 2053–2108 (2019).
   PubMed Web of Science ®Google Scholar
• Karimi M , GhasemiA, SahandiZangabad Pet al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev.45(5), 1457–1501 (2016).
   PubMed Web of Science ®Google Scholar
• Fan W , YungB, HuangP, ChenX. Nanotechnology for multimodal synergistic cancer therapy. Chem. Rev.117(22), 13566–13638 (2017).
   PubMed Web of Science ®Google Scholar
• Wilhelm S , TavaresA, DaiQEA. Analysis of nanoparticle delivery to tumors. Nat. Rev. Mater.1(5), 16014 (2016).
   Web of Science ®Google Scholar
• Shi J , KantoffPW, WoosterR, FarokhzadOC. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer17(1), 20–37 (2017).
   PubMed Web of Science ®Google Scholar
• Khawar IA , KimJH, KuhHJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J. Control. Release201, 78–89 (2015).
   PubMed Web of Science ®Google Scholar
• Maeda H , NakamuraH, FangJ. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev.65(1), 71–79 (2013).
   PubMed Web of Science ®Google Scholar
• Nicolas J , MuraS, BrambillaD, MackiewiczN, CouvreurP. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem. Soc. Rev.42(3), 1147–1235 (2013).
   PubMed Web of Science ®Google Scholar
• Lv Y , XuC, ZhaoXet al. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells. ACS Nano12(2), 1519–1536 (2018).
   PubMed Web of Science ®Google Scholar
• Cai R , ChenC. The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater.31(45), 1805740 (2019).
   PubMed Web of Science ®Google Scholar
• Rosenblum D , JoshiN, TaoW, KarpJM, PeerD. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun.9(1), 1410 (2018).
   PubMed Web of Science ®Google Scholar
• Owens DE 3rd , PeppasNA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm.307(1), 93–102 (2006).
   PubMed Web of Science ®Google Scholar
• Blanco E , ShenH, FerrariM. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol.33(9), 941–951 (2015).
   PubMed Web of Science ®Google Scholar
• Zou Y , ItoS, YoshinoF, SuzukiY, ZhaoL, KomatsuN. Polyglycerol grafting shields nanoparticles from protein corona formation to avoid macrophage uptake. ACS Nano14(6), 7216–7226 (2020).
   PubMed Web of Science ®Google Scholar
• Rudnick SI , LouJ, ShallerCCet al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res.71(6), 2250–2259 (2011).
   PubMed Web of Science ®Google Scholar
• Chauhan VP , StylianopoulosT, MartinJDet al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol.7(6), 383–388 (2012).
   PubMed Web of Science ®Google Scholar
• Donahue ND , AcarH, WilhelmS. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev.143, 68–96 (2019).
   PubMed Web of Science ®Google Scholar
• Kinnear C , MooreTL, Rodriguez-LorenzoL, Rothen-RutishauserB, Petri-FinkA. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem. Rev.117(17), 11476–11521 (2017).
   PubMed Web of Science ®Google Scholar
• Behzadi S , SerpooshanV, TaoWet al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev.46(14), 4218–4244 (2017).
   PubMed Web of Science ®Google Scholar
• Kirpotin DB , DrummondDC, ShaoYet al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res.66(13), 6732–6740 (2006).
   PubMed Web of Science ®Google Scholar
• Hühn D , KantnerK, GeidelCet al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano7(4), 3253–3263 (2013).
   PubMed Web of Science ®Google Scholar